Rosario Maselli

Medicine · Health Sciences

27h-index2.6kcitations79works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Asthma and respiratory diseases(43), Chronic Obstructive Pulmonary Disease (COPD) Research(11), Cytokine Signaling Pathways and Interactions(11), Respiratory and Cough-Related Research(11), IL-33, ST2, and ILC Pathways(11)

Publications79 total

Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes
The Journal of Allergy and Clinical Immunology In Practice·2019· 8 cited
Dupilumab for the treatment of asthma
Expert Opinion on Biological Therapy·2017· 49 cited
Knowledge of HIV infection and transmission: a knowledge, attitudes, beliefs and practices (KABP) survey among a sample of students at the "Magna Graecia", University of Catanzaro.
PubMed·2017· 8 cited
Theophylline action on primary human bronchial epithelial cells under proinflammatory stimuli and steroidal drugs: a therapeutic rationale approach
Drug Design Development and Therapy·2017· 18 citedOpen Access
Anti-TNF-α Therapies
2016
Anti-IgE Therapy
2016· 1 cited
Other Biologic Drugs
2016
Airway Remodelling in Asthma
2016· 4 cited
Asthma: Targeted Biological Therapies
2016· 5 cited
IL-5-Targeted Antibodies
2016
Introduction
2016
Biologic Treatments Targeted to Innate Cytokines
2016
Anti-IL-4/IL-13 Biologics
2016· 2 cited
Inflammatory Cellular Patterns in Asthma
2016
Conclusions and Future Perspectives
2016
Molecular and cellular mechanisms underlying the therapeutic effects of budesonide in asthma
Pulmonary Pharmacology & Therapeutics·2016· 35 cited
Role of biologics in severe eosinophilic asthma – focus on reslizumab
Therapeutics and Clinical Risk Management·2016· 52 citedOpen Access
Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPD
Therapeutics and Clinical Risk Management·2015· 18 citedOpen Access
Pharmacological basis and scientific rationale underlying the targeted use of inhaled corticosteroid/long-acting β<sub>2</sub>-adrenergic agonist combinations in chronic obstructive pulmonary disease treatment
Expert Opinion on Pharmacotherapy·2015· 24 cited
Anti-IgE Therapy with Omalizumab for Severe Asthma: Current Concepts and Potential Developments
Current Drug Targets·2015· 27 cited
page 1 of 4Next →

Frequent Co-authors

Girolamo Pelaia(43), Alessandro Vatrella(32), Luca Gallelli(27), S. A. Marsico(18), Maria Teresa Busceti(13), Rosa Terracciano(11), Teresa Renda(10), Giovanni Cuda(8), Rocco Savino(8), M Caputi(7), Cecilia Calabrese(6), Francesco Costanzo(6), D. Fratto(6), Bruno D’Agostino(6), Rosa Daniela Grembiale(5), Giovambattista De Sarro(5), Mario Cazzola(4), Michele Caraglia(3), Pierluigi Paggiaro(3), Nunzio Crimi(3)